{"nctId":"NCT01902134","briefTitle":"Oral Treatment for Orthopaedic Post-operative Pain With Dexketoprofen Trometamol and Tramadol Hydrochloride","startDateStruct":{"date":"2013-04"},"conditions":["Acute Pain"],"count":641,"armGroups":[{"label":"DKP/TRAM followed by DKP/TRAM","type":"EXPERIMENTAL","interventionNames":["Drug: Dexketoprofen/Tramadol-single dose","Drug: Dexketoprofen/Tramadol-multiple doses"]},{"label":"DKP followed by DKP","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Dexketoprofen-single dose","Drug: Dexketoprofen-multiple doses"]},{"label":"TRAM followed by TRAM","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Tramadol-single dose","Drug: Tramadol-multiple doses"]},{"label":"Placebo followed by DKP/TRAM","type":"OTHER","interventionNames":["Drug: Placebo","Drug: Dexketoprofen/Tramadol-multiple doses"]},{"label":"Placebo followed by DKP","type":"OTHER","interventionNames":["Drug: Placebo","Drug: Dexketoprofen-multiple doses"]},{"label":"Placebo followed by TRAM","type":"OTHER","interventionNames":["Drug: Placebo","Drug: Tramadol-multiple doses"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Tramadol-single dose","otherNames":[]},{"name":"Dexketoprofen-single dose","otherNames":[]},{"name":"Dexketoprofen/Tramadol-single dose","otherNames":[]},{"name":"Tramadol-multiple doses","otherNames":[]},{"name":"Dexketoprofen-multiple doses","otherNames":[]},{"name":"Dexketoprofen/Tramadol-multiple doses","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female patients aged 18 to 80 years. Females participating in the study must be either of non-childbearing potential, or willing to use a highly effective contraceptive method.\n* Scheduled to undergo standard primary (first-time) one-sided total hip replacement surgery due to primary osteoarthritis.\n* Patients experiencing pain at rest of at least moderate intensity the day after surgery.\n\nExclusion Criteria:\n\n* Patients not suitable for study treatments and rescue medication (RM) or those for whom non-steroidal anti-inflammatory drugs (NSAIDs), opioids, acetyl salicylic acid, pyrazolones or pyrazolidines are contraindicated.\n* Patients with clinically significant abnormalities in vital signs, safety laboratory tests and 12-lead ECG at screening.\n* Patients with history of any illness or condition that might pose a risk to the patient or confound the efficacy and safety study results.\n* Patients using and not suitable to withdraw analgesics other than those specified in the protocol.\n* Patients using and not suitable for withdrawing any of the prohibited medication specified in the protocol.\n* Pregnant and breastfeeding women.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"SPID8 (Sum of Pain Intensity Differences Over 8 Hours)","description":"Sum of Pain Intensity Differences calculated as the weighted sum of the PI-VAS differences over 8 hour period. PI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale (0=no pain to 100=worst pain imaginable) which was measured at 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, and 8h after the first dose. A higher value in SPID indicates greater pain relief.\n\nThe analysis was performed combining all randomization arms including placebo into one group, which resulted in the following 4 analysis groups: DKP/TRAM, DEXKETOPROFEN, TRAMADOL, and Placebo.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"246.9","spread":"156.50"},{"groupId":"OG001","value":"208.8","spread":"154.69"},{"groupId":"OG002","value":"204.6","spread":"145.79"},{"groupId":"OG003","value":"151.1","spread":"158.51"}]}]}]},{"type":"SECONDARY","title":"SPID48 (Sum of Pain Intensity Differences Over First 48 Hours of the Multiple-dose Phase)","description":"Sum of Pain Intensity Differences calculated as the weighted sum of the PI-VAS differences over 48 hours of the multiple-dose phase.\n\nPI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale (0=no pain to 100=worst pain imaginable) which was measured every two hours over the first 48 hours of the multiple-dose phase. A higher value in SPID indicates greater pain relief.\n\nThe analysis was performed combining all randomization arms including the same active treatment, which resulted in the following 3 analysis groups: DKP/TRAM, DEXKETOPROFEN, and TRAMADOL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1943.7","spread":"1000.51"},{"groupId":"OG001","value":"1677.5","spread":"1070.91"},{"groupId":"OG002","value":"1765.6","spread":"963.49"}]}]}]},{"type":"SECONDARY","title":"Percentage of Responders According to PI-VAS (Pain Intensity - Visual Analogue Scale)","description":"Percentage of responders; response defined as achievement a mean pain intensity, PI-VAS \\< 40 mm (PI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale, 0=no pain to 100=worst pain imaginable),over 48 hours of the multiple-dose phase.\n\nThe analysis was performed combining all randomization arms including the same active treatment, which resulted in the following 3 analysis groups: DKP/TRAM, DEXKETOPROFEN, and TRAMADOL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.1","spread":null},{"groupId":"OG001","value":"76.6","spread":null},{"groupId":"OG002","value":"82.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Responders According to 50% Max TOTPAR (Total Pain Relief)","description":"Percentage of responders over 8 hours after first dose, according to the 50% maximum total pain relief rule: maximum TOTPAR calculated as the theoretical maximum weighted sum of PAR-VRS (Pain Relief - Verbal Rating Scale: pain relief 0=none, 4=complete) scores.\n\nThe analysis was performed combining all randomization arms including placebo into one group, which resulted in the following 4 analysis groups: DKP/TRAM, DEXKETOPROFEN, TRAMADOL, and Placebo.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.9","spread":null},{"groupId":"OG001","value":"56.5","spread":null},{"groupId":"OG002","value":"51.9","spread":null},{"groupId":"OG003","value":"37.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":159},"commonTop":["Pyrexia","Anaemia postoperative","Nausea","Anaemia"]}}}